关键词: 癌, 非小细胞肺, 药物疗法, 免疫, 生活质量, 消癌平注射液

Abstract: Objective To explore the shortterm efficacy of Xiaoaiping injection assisted TP regimen (taxotere + paraplatin) in the treatment of advanced nonsmall cell lung cancer (NSCLC) and its effects on immune function, adverse reactions and quality of life. Methods Onehundred cases of patients with advanced NSCLC who were admitted to the Affiliated Hospital of Chengdu University of Traditional Chinese Medicine from October 2014 to October 2017 were selected as subjects, and they were randomly divided into Xiaoaiping group (n=55) and TP group (n=45) according to the random number table method. Patients in TP group were given TP regimen chemotherapy, and patients in Xiaoaiping group were added with Xiaoaiping injection on the basis of TP group. The shortterm efficacy and changes of immune function, adverse reactions and quality of life were observed in the two groups, and statistical comparison was performed. ResultsAfter treatment, the response rates of patients in Xiaoaiping group and TP group were 49.09% (27/55) and 28.89% (13/45) respectively, with a significant difference (χ2=4.209, P=0.040). After treatment, the disease control rates of patients in Xiaoaiping group and TP group were 83.64% (46/55) and 73.33% (33/45) respectively, with no significant difference (χ2=1.584, P=0.208). The CD4+ (40.98%±5.73% vs. 33.47%±5.06%), CD4+/CD8+ (1.53±0.34     vs. 1.25±0.26) and nature killer (NK) cells (19.59%±4.77% vs. 17.05%±4.12%) in Xiaoaiping group after treatment were significantly higher than those in TP group (t=6.869, P＜0.001; t=4.542, P＜0.001; t=5.609, P＜0.001). And there was no significant difference in CD8+ between the two groups (26.83%±5.21% vs. 26.58%±5.20%; t=0.239, P=0.812). The incidence rates of leucopenia (50.91% vs. 75.56%), thrombocytopenia (38.18% vs. 66.67%) and hemoglobin reduction (52.73% vs. 77.78%) in Xiaoaiping group were lower than those in TP group, with significant differences (χ2=6.381, P=0.012; χ2=8.306, P=0.005; χ2=6.741, P=0.009). There were no significant differences in the incidence rates of nausea and vomiting (32.73% vs. 48.89%), diarrhea constipation (45.45% vs. 60.00%)  and liver damage (7.27% vs. 13.33%) between the two groups (χ2=2.694, P=0.101; χ2=2.098, P=0.148; χ2=0.449, P=0.503). After treatment, the Karnofsky functional status scores of patients in Xiaoaiping group and TP group were 81.47±11.26 and 73.38±10.45  respectively, and the stability rates of quality of life improvement were 78.18% (43/55) and 57.78% (26/45) respectively, with significant differences (t=3.691, P＜0.001; χ2=4.817, P=0.028). Conclusion Xiaoaiping injection assisted TP regimen has a good shortterm efficacy on advanced NSCLC, which can effectively improve immune function, reduce adverse reactions and improve the quality of life.

Key words: Carcinoma, non-small-cell lung, Drug therapy, Immunity, Quality of life, Xiaoaiping injection